ClinicalTrials.gg
Not yet recruitingNCT06635772Updated Oct 10, 2024

A Study of the Effect and Safety of HS-10390 in the Treatment of Patients with Primary IgA Nephropathy

A Phase 2 interventional study of HS-10390 and Irbesartan in Immunoglobulin a Nephropathy, sponsored by Hansoh BioMedical R&D Company. Not yet recruiting at 1 site in China. Open to participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2024-10-10.

Sponsored by Hansoh BioMedical R&D Company (part of Hansoh Pharmaceutical Group Company Limited) · Phase 2, Interventional, and Treatment

From the registry’s dates

  • Primary completion was expected by Dec 2025, 11 months ago, but the record still lists the study as not yet recruiting.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
90
Allocation
Randomized
Ages
18 Years to 65 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 127 studies in Glomerulonephritis, IGA with a site in China — 58 open to participants now, 73 under way, 20 of them phase 3. Glomerulonephritis, IGA · China.

Planned enrollment
51st of 109
90 · median 84
Started
2024
with 11 others
Phase 2
27 of 127
14 open now
Primary completion
2025-12
later than 10 of 72 live
Registered
73rd of 127
by date

Among the 127 studies in Glomerulonephritis, IGA with a site in China, this one is the 51st largest by planned enrollment of the 109 interventional ones that give a count, is one of 12 that started in 2024, is one of 27 in phase 2, reaches primary completion later than 10 of the 72 other live ones, and was the 73rd registered.

Glomerulonephritis, IGA

276 studies on the registry are indexed under Glomerulonephritis, IGA; 108 are open to participants now.

Browse Glomerulonephritis, IGA studies →

Open to participants now

58 of the 127 studies in Glomerulonephritis, IGA with a site in China are open now. Recruiting first, the newest first:

53 more — sign in →

All 58 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 68 Glomerulonephritis, IGA studies recruiting now, 39 (57%) set no upper age limit and 24 (35%) stop at 75 or younger; 21 take children under 18; 5 take healthy volunteers.

This study: 18 Years to 65 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 127 studies in Glomerulonephritis, IGA with a site in China, or all of them as a file.
02

Study summary

This study will evaluate the efficacy and safety of HS-10390 in subjects with primary IgA nephropathy, and explore the optimal dose for the treatment.

03

Conditions studied

  • Immunoglobulin a Nephropathy

Keywords

  • Immunoglobulin A Nephropathy
04

Who can participate

Ages eligible
18 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Male or female, between 18 and 65 years age.
  • -proven primary IgA nephropathy.
  • Currently on stable dose of ACEI and/or ARB therapy, for at least 12 weeks prior to screening (the patient's maximum tolerated dose and is at least one-half of the maximum labeled dose).
  • Average 24-hour urine total protein ≥ 0.75 g/24 h at screening.
  • Estimated (using the CKD-EPI 2009) ≥ 30 mL/min per 1.73 m\^2 at screening.
  • Systolic BP between 100 and 150 mmHg and diastolic BP between 60 and 100 mmHg.

Exclusion criteria

Exclusion Criteria:

  • IgA nephropathy secondary to another condition
  • IgA nephropathy with rapid decline of renal function; Kidney pathology indicated that more than 50% of the glomerulus had large crescent body formation, which may affect the study results; Tubule atrophy - interstitial fibrosis of more than 50%;
  • Chronic kidney disease (CKD) in addition to IgAN
  • Patients treated with any systemic non-biologic drugs (including systemic ) within 12 weeks prior to randomizing;
  • Require any prohibited medications prior to randomizing;
  • Exposure to an drug within 30 days or 5 half-lives (whichever is longer) prior to screening
  • History of organ transplantation, with exception of corneal transplants
  • \< 100×109/L or value \< 90 g/L) or Hematocrit value \< 27% (0.27 V/V) at Screening
  • Elevations of transaminases ( and/or AST) >2 times or total and/or direct bilirubin exceeding 1.5 times the upper limit of normal (ULN) at screening
  • Potassium >5.5 mmol/L at Screening
Terms in these criteria, in plain language(10)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
90 participants (estimated)

Study arms

  • Experimental
    HS-10390; high dose

    HS-10390; high dose

    Drug: HS-10390

  • Experimental
    HS-10390; low dose

    HS-10390; low dose

    Drug: HS-10390

  • Active comparator
    irbesartan

    Irbesartan will be administered daily as a 150-mg oral tablet. For patients who tolerate the initial dose of 150 mg after 2 weeks will increase their dose to 300 mg

    Drug: Irbesartan

Interventions

  • HS-10390 will be administered daily

  • Irbesartan will be administered daily as a 150-mg oral tablet. For patients who tolerate the initial dose of 150 mg after 2 weeks will increase their dose to 300 mg

06

What researchers measure

Primary outcomes

  1. Change from baseline in 24-hour urine protein at Week 12

    The change in urine protein: creatinine ratio (UPCR) from baseline to Week 12

    Time frame: up to week 12

Secondary outcomes

  1. Change from baseline in 24-hour urine protein (UPCR)

    The change in urine protein: creatinine ratio (UPCR) from baseline

    Time frame: up to Week 12

  2. Change from baseline in 24-hour urine protein(UACR)

    The change in urine albumin: creatinine ratio (UACR) from baseline

    Time frame: up to Week 12

  3. Change from baseline in 24-hour urine protein

    The change in urine protein excretion from baseline

    Time frame: up to Week 12

  4. Proportion Change from baseline in 24-hour urine protein

    The proportion of patients with urinary protein equivalent of \< 0.3 g/24 hours

    Time frame: up to Week 12

  5. change from baseline in Estimated Glomerular Filtration Rate

    change from baseline in Estimated Glomerular Filtration Rate (eGFR)

    Time frame: up to Week 12

  6. Number of subjects with adverse events (AEs)

    Type, incidence, severity, seriousness, and relatedness of AEs will be collected

    Time frame: up to Week 12

  7. Plasma Concentration of HS-10390

    Blood samples will be collected for the measurement of plasma concentrations of HS-10390

    Time frame: up to Week 12

07

Study locations

1 site
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Nov 2024; primary completion for Dec 2025, 13 months later.

Of 41 phase 2 interventional studies under Glomerulonephritis, IGA, half reached primary completion within 33 months of starting (the median), counting those still running; a quarter within 17 and three quarters within 50. This study's planned 13 months is below that.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 8, 2024
First posted
Oct 10, 2024
StartEst.
Nov 2024
Primary completionEst.
Dec 1, 2025
CompletionEst.
Apr 30, 2026
Last update
Oct 10, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Oct 10, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT06635772
Responsible party
Sponsor
First posted
Oct 10, 2024
Start date
Nov 2024 (estimated)
Primary completion
Dec 1, 2025 (estimated)
Completion
Apr 30, 2026 (estimated)
Last update
Oct 10, 2024

Study contacts

jicheng Lv, PhD
Contact
chenglv@263.net
+8613161753111

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Oct 2024. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: HS-10390

Start the discussion